Sangmin Lee is an Oncology physician affiliated with Johnson & Johnson. OpenAlex indexes 31 publications with 676 citations (h-index 14); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
520 E 70th St. Starr 341
New York, NY 100219800
Telephone
646-962-2700Registry record last updated 15 Oct 2013.
Clinical trials
- Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML
Sponsor: Weill Medical College of Cornell University
- Risk Factors of Sternal Wound Infection After Coronary Artery Bypass Graft
Sponsor: Samsung Medical Center
- Verification of Appropriate Insertion Depth of Endotracheal Tube Placement
Sponsor: Samsung Medical Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Global Services, LLCProgram year20251 payment
- ABBVIE INC.Program year20221 payment
- Takeda Pharmaceuticals U.S.A., Inc.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2021)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
57.1%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor28.6%Valacyclovir100%Part D≥13 patientsAzole Antifungal10.7%Fluconazole54%Posaconazole46%Part D<11 patients+ 3 more classes in this area
Cancer & immunology
27.7%Antimetabolite13.8%Hydroxyurea100%Part D≥11 patientsKinase inhibitor13.8%Imatinib Mesylate61%Jakafi39%Part D<11 patientsMusculoskeletal
9.8%Xanthine oxidase inhibitor9.8%Allopurinol100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Wayne Drevets, MD
Johnson & Johnson
Matthew Breyer, MD
Johnson & Johnson
Deepu Madduri, MD
Johnson & Johnson
Elliot Barnathan, MD
Johnson & Johnson
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”